Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >-30 days and ≤90 days from conception (SHORT_EXP), and describing newborns' outcomes.

Landi, D., Bovis, F., Grimaldi, A., Annovazzi, P. O., Bertolotto, A., Bianchi, A., Borriello, G., Brescia Morra, V., Bucello, S., Buscarinu, M. C., Caleri, F., Capobianco, M., Capra, R., Cellerino, M., Centonze, D., Cerqua, R., Chisari, C. G., Clerico, M., Cocco, E., Cola, G., Cordioli, C., Curti, E., D'ambrosio, A., D'amico, E., De Luca, G., Di Filippo, M., Di Lemme, S., Fantozzi, R., Ferraro, D., Ferraro, E., Gallo, A., Gasperini, C., Granella, F., Inglese, M., Lanzillo, R., Lorefice, L., Lus, G., Malucchi, S., Margoni, M., Mataluni, G., Mirabella, M., Moiola, L., Nicoletti, C. G., Nociti, V., Patti, F., Pinardi, F., Portaccio, E., Pozzilli, C., Ragonese, P., Rasia, S., Salemi, G., Signoriello, E., Vitetta, F., Totaro, R., Sormani, M. P., Amato, M. P., Marfia, G. A., Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis, <<JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY>>, 2022; 2022 (sep 30): N/A-N/A. [doi:10.1136/jnnp-2022-329657] [http://hdl.handle.net/10807/216172]

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

Mirabella, Massimiliano;Nociti, Viviana;
2022

Abstract

Assessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >-30 days and ≤90 days from conception (SHORT_EXP), and describing newborns' outcomes.
Inglese
Landi, D., Bovis, F., Grimaldi, A., Annovazzi, P. O., Bertolotto, A., Bianchi, A., Borriello, G., Brescia Morra, V., Bucello, S., Buscarinu, M. C., Caleri, F., Capobianco, M., Capra, R., Cellerino, M., Centonze, D., Cerqua, R., Chisari, C. G., Clerico, M., Cocco, E., Cola, G., Cordioli, C., Curti, E., D'ambrosio, A., D'amico, E., De Luca, G., Di Filippo, M., Di Lemme, S., Fantozzi, R., Ferraro, D., Ferraro, E., Gallo, A., Gasperini, C., Granella, F., Inglese, M., Lanzillo, R., Lorefice, L., Lus, G., Malucchi, S., Margoni, M., Mataluni, G., Mirabella, M., Moiola, L., Nicoletti, C. G., Nociti, V., Patti, F., Pinardi, F., Portaccio, E., Pozzilli, C., Ragonese, P., Rasia, S., Salemi, G., Signoriello, E., Vitetta, F., Totaro, R., Sormani, M. P., Amato, M. P., Marfia, G. A., Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis, <<JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY>>, 2022; 2022 (sep 30): N/A-N/A. [doi:10.1136/jnnp-2022-329657] [http://hdl.handle.net/10807/216172]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/216172
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact